Literature DB >> 17915087

Sulfasalazine in undifferentiated spondyloarthropathies.

Mazen Elyan, Muhammad Asim Khan.   

Abstract

Entities:  

Year:  2007        PMID： 17915087

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  9 in total

1.  Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.

Authors:  F Van den Bosch; E Kruithof; D Baeten; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; M Dougados; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

3.  Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.

Authors:  Jan Brandt; Hildrun Haibel; Jaqueline Reddig; Joachim Sieper; Jürgen Braun
Journal:  J Rheumatol       Date:  2002-01       Impact factor: 4.666

Review 4.  Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy.

Authors:  Nurullah Akkoc; Sjef van der Linden; Muhammad Asim Khan
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-06       Impact factor: 4.098

5.  Low dose of infliximab is inadequate in most patients with spondylarthropathies.

Authors:  P Sidiropoulos; H D Kritikos; P Siakka; M Mamoulaki; H Kouroumali; K Voudouris; D T Boumpas
Journal:  Clin Exp Rheumatol       Date:  2005 Jul-Aug       Impact factor: 4.473

Review 6.  Sulfasalazine for ankylosing spondylitis.

Authors:  J Chen; C Liu
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

7.  Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study.

Authors:  M Breban; E Vignon; P Claudepierre; V Devauchelle; D Wendling; E Lespessailles; L Euller-Ziegler; J Sibilia; A Perdriger; M Mezières; C Alexandre; M Dougados
Journal:  Rheumatology (Oxford)       Date:  2002-11       Impact factor: 7.580

8.  Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms.

Authors:  F Van den Bosch; E Kruithof; M De Vos; F De Keyser; H Mielants
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

9.  Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup.

Authors:  W Mau; H Zeidler; R Mau; A Majewski; J Freyschmidt; W Stangel; H Deicher
Journal:  J Rheumatol       Date:  1988-07       Impact factor: 4.666
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.